Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

3Total

P 1 (1)

P 2 (2)

Trial Status

Completed2

Enrolling By Invitation1

Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT03655223Enrolling By Invitation

Early Check: Expanded Screening in Newborns

NCT02047461Phase 2CompletedPrimary

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

NCT02629393Phase 2CompletedPrimary

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

NCT00957749Phase 1WithdrawnPrimary

Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A

Showing all 4 trials

Molybdenum Cofactor Deficiency, Type A